MDT-AP-2921
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 1
- sex
- M
- new_clusters
- S2
- umap1_2d
- -1.599489779
- umap2_2d
- -8.416311516
- umap1_3d
- -3.300082755
- umap2_3d
- -1.91876175
- umap3_3d
- 5.500415919
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.580
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- INFLAMMATORY_RESPONSE+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- ALLOGRAFT_REJECTION+0.430
- COAGULATION+0.410
- KRAS_SIGNALING_UP+0.400
- TNFA_SIGNALING_VIA_NFKB+0.380
- COMPLEMENT+0.360
Top 10 suppressed
- DNA_REPAIR-0.410
- MYC_TARGETS_V2-0.360
- MITOTIC_SPINDLE-0.340
- MYC_TARGETS_V1-0.300
- G2M_CHECKPOINT-0.260
- E2F_TARGETS-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.200
- OXIDATIVE_PHOSPHORYLATION-0.190
- HEME_METABOLISM-0.160
- PI3K_AKT_MTOR_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_6P50QTPP | low-grade glioma | — | 0.928 |
| 2 | MDT-AP-2936 | Med | Medulloblastoma | 0.926 |
| 3 | sclc0617_S65.txt | — | cohortMD2 | 0.924 |
| 4 | BS_W97QQYKQ | Ganglioglioma | — | 0.923 |
| 5 | BS_KXH37MPN | DNET | — | 0.920 |
| 6 | BS_AP0SZ364 | low-grade glioma | — | 0.916 |
| 7 | MDT-AP-2584 | Med | Medulloblastoma | 0.915 |
| 8 | MDT-AP-0484 | Med | Medulloblastoma | 0.915 |
| 9 | BS_5NWDARXG | pilocytic astrocytoma | — | 0.915 |
| 10 | sclc1896_S36.txt | — | cohortMD2 | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.340 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |